Except for acute promyelocytic leukemia (APL) [1] and—recently—FLT3 mutated AML [2], the substantial (genetic) heterogeneity of AML [3, 4] so far has had only a moderate impact on the choice of therapy. The gene discussed is FLT3; the disease is acute promyelocytic leukemia.